Japan’s Daiichi Sees Lower Earnings Impact Than Other M&As
This article was originally published in PharmAsia News
Executive Summary
Unlike other Japanese drug makers who made major acquisitions this year, Daiichi Sankyo is expected to weather the usual damage to earnings reports, the firm says. Daiichi said it would purchase by next spring a greater than 50 percent of India's Ranbaxy Laboratories. Japanese competitors of Daiichi have experienced large drops in earnings in the wake of similar major acquisitions, such as Eisai's buy of MGI Pharma and Takeda Pharmaceutical's purchase of Millennium Pharmaceuticals. One reason Daiichi looks to come out on the positive end is its purchase of a generics maker with low research and development expenses. (Click here for more - a subscription may be required